NCT00793572 · OUTCOME

Number of Patients With Non-relapse Mortality

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 200 and 365 days after allo

What was measured

Number of subjects with non-relapse mortalities post allogeneic transplant.

Groups in this outcome

Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy

See Detailed Description Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation Bortezomib: Given SC Cyclosporine: Given IV Cyclosporine: Given PO Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Melphalan: Given IV Mycophenolate Mofetil: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation Peripheral Blood Stem Cell Transplantation: Undergo transplantation Syngeneic Bone Marrow Transplantation: Undergo transplantation Total-Body Irradiation: Undergo radiotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	32

Reported measurements

200 days post allo

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	1	Not reported	Not reported	Not reported	Not reported

1 Year post allo

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1
title
200 days post allo
categories
measurements
group Id
OG000
value
1
title
1 Year post allo

denoms

counts
group Id
OG000
value
32
units
Participants

description

Number of subjects with non-relapse mortalities post allogeneic transplant.

groups

description
See Detailed Description Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation Bortezomib: Given SC Cyclosporine: Given IV Cyclosporine: Given PO Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Melphalan: Given IV Mycophenolate Mofetil: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation Peripheral Blood Stem Cell Transplantation: Undergo transplantation Syngeneic Bone Marrow Transplantation: Undergo transplantation Total-Body Irradiation: Undergo radiotherapy
id
OG000
title
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

200 and 365 days after allo

title

Number of Patients With Non-relapse Mortality

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice